329results about "Chemokines" patented technology

The invention discloses a recombinant fibronectin fusion protein and application thereof. The recombinant fibronectin fusion protein comprises a recombinant fibronectin mutant (FN1) and a platelet factor 4 (PF4), the amino acid sequence of the recombinant fibronectin is as shown in SEQ ID NO. 3 or SEQ ID NO. 4. The molecular weight of the recombinant fibronectin fusion protein is less than 90KDa, and the recombinant fibronectin fusion protein is good in solubility, simple in preparation process and convenient to purify; the recombinant fibronectin provided by the invention has novel recombinant fibronectin, and can inhibit inflammation in a wound healing process, so that mouse skin injury healing is efficiently promoted, and a new thought can be provided for development of wound healing drugs. In addition, when the platelet factor 4 is creatively fused to the N end of the fibronectin mutant, the cell proliferation activity can be obviously and effectively promoted.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

An implantable or injectable scaffold comprising an antigen, a T memory cell inducer, and other optional components is provided for use in enhancing the immune response to the antigen, in particular for subjects who are elderly, immunosenescent and / or immunocompromised, or undergoing cancer therapy. Coronavirus SARS-CoV-2 has caused millions of confirmed cases and hundreds of thousands of deaths. However, there is no effective drug treatment, and vaccine is in great need to control the spread of such highly infectious virus.

Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.

The invention discloses an application of CXCL11 as an antiviral drug, relates to the field of biological medicines, and in particular relates to a protein of an antiviral drug, and the protein as the antiviral drug can inhibit infection and replication of RSV (Respiratory Syndrome Virus). The invention also provides a technical enlightenment for taking a related host protein in a virus infection pathway as an antiviral drug research target, and an application related indication of the CXCL11 protein analogue to clinical symptoms and / or clinical indications caused by severe respiratory syncytial virus infection. The invention further provides an administration route of the CXCL11 serving as an antiviral drug, a dosage range of drug intervention and the like, and finally, the feasibility of the CXCL11 serving as the antiviral drug is further verified through drug intervention application after drug challenge in CXCL11 <- / -> mice.

Provided herein are nucleic acid vaccine constructs comprising synthetic polynucleotides encoding a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) protein, or a functional portion, fragment, or variant thereof, conjugated to a macrophage inflammatory protein-3 alpha (MIP-3a) or other chemokine that binds to a chemokine receptor 6 (CCR6), or a functional portion, fragment, or variant thereof, or to an antibody, or antigen binding portion thereof, that binds to a CCR6. Methods for making the vaccine constructs and their use in prophylaxis and treatment of SARS-CoV-2 infections are also provided.

The technology described herein is directed to engineered MCP proteins and engineered PCP proteins, which are degraded when the proteins are not bound to an MS2 or PP7 RNA hairpin loop, respectively. Also described herein are fusion proteins comprising such engineered MCP proteins and engineered PCP proteins linked to various effector proteins. The linkage to the effector proteins can be modulated through of specialized linker domains. In addition, described herein are complexes and systems comprising the fusion proteins in combination with synthetic RNA molecules, in order to modulate the structure and / or function the synthetic RNA molecules.

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines / chemokines / transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and / or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and / or CAR-T associated neuropathy.

The present invention discloses a novel coronavirus nano-vaccine with targeted synergistic effect, belonging to the field of vaccines. The active ingredient of the vaccine is a fusion protein, which includes the amino acid sequence of the RBD domain of the novel coronavirus. The N-terminus of the amino acid sequence of the RBD domain is connected to XCL1 through a flexible linker GSG, and the C-terminus of the RBD domain sequence is connected to the Ferritin protein through a flexible linker GSG. The purified XCL1-RBD-Ferritin can be assembled into nanoparticles of 24-mers, improving the efficiency of RBD antigen in activating DCs, especially DC1s, thereby efficiently initiating humoral and cellular immune responses.

The present disclosure relates to CXCR3 ligands having CXCR3-expressing-cell migration-inducing activity, and specifically to amino acid modifications and amino acid sequences that are important for CXCR3-expressing-cell migration-inducing activity.

The present invention relates to a ligand binding molecule whose ligand binding activity is attenuated by the cleavage of a cleavage site and a method for producing the same, a complex formed by the ligand binding molecule and a ligand, a fusion protein comprising the ligand binding molecule and a ligand, and a pharmaceutical composition comprising the ligand binding molecule or a fusion protein of the ligand binding molecule and a ligand.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The present invention provides a pluripotent stem cell expressing the following (a) and (b): (a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B) (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.

The invention provides an engineered immune cell for jointly expressing XCL1 and Flt3l as well as preparation and application of the engineered immune cell. The XCL1 and the Flt3l are jointly expressed in the T cells at the same time, migration and functions of the DC can be remarkably promoted, interaction between the DC and the T cells is improved, and the number of TCF1 + SlamF6 + dry T cells is maintained. The engineered immune cell provided by the invention can synergistically and remarkably improve the killing effect on tumors.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

To provide: in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome; and the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SOLUTION: The present invention provides, in the field of oncolytic viruses, in particular a recombinant rhabdovirus, such as vesicular stomatitis virus encoding a CCL21 protein in its genome. The invention further provides the use of the recombinant virus in treatment of cancer, and also methods for producing such viruses.SELECTED DRAWING: None

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

A chemokine mixture suitable for modulating an immune response, comprising a first chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR4, and a second chemokine, or an agonist or antagonist mutant thereof, suitable for binding to CCR5 and / or CCR6.

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The present invention relates to novel peptides, compositions and kits comprising said peptides, for use as active ingredients for preventing or treating pain in a subject in need thereof. In vitro or ex vivo methods for modulating the expression of these peptides are also described herein.

The present disclosure relates to recombinant oncolytic viral vectors for the treatment and prevention of cancers such as glioblastoma. The oncolytic viral vectors comprise one or more of the following features: miRNA target sequence(s) for viral replication restriction; transgene(s) encoding one or more payload molecules; a retargeting domain; mutation(s) in both UL30 and UL23 genes; and a protein with a syncytial mutation and a counterpart protein without the syncytial mutation.

A method of stabilizing a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 is provided. The method comprises the step of introducing the chemokine proteins into a solution comprising a buffer a non- ionic or amphoteric surfactant; and an aqueous chaotropic agent. A method of detecting a chemokine protein with a C-X-C or a C-C structural motif such as CXCL13 and CCL21 conjugated to antibodies thereto labelled with a fluorescent label in a solution is also provided. The method comprises the following steps: providing a test substrate comprising an elongate nitro cellulose membrane.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

The invention discloses a preparation method and application of an engineered neutrophil liposome drug for enhancing an anti-tumor immune effect, and finds that the combination of a neutrophil membrane liposome carrying CXCL9 and a CAR-T cell targeting B7-H3 has a synergistic treatment effect on solid tumors such as lung cancer for the first time. The invention provides a brand new effective drug combination strategy for the treatment of solid tumors such as lung cancer, and has important scientific significance and clinical application value in the technical field of development of drugs for treating solid tumors such as lung cancer.